X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (15867) 15867
Newsletter (6662) 6662
Book Review (1607) 1607
Publication (1029) 1029
Newspaper Article (365) 365
Magazine Article (190) 190
Conference Proceeding (117) 117
Dissertation (61) 61
Book Chapter (55) 55
Trade Publication Article (53) 53
Reference (20) 20
Government Document (18) 18
Transcript (5) 5
Book / eBook (3) 3
Data Set (2) 2
Journal / eJournal (2) 2
Paper (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
cox-2 inhibitors (16223) 16223
index medicus (10303) 10303
humans (6134) 6134
animals (5339) 5339
cox-2 (5260) 5260
research (4798) 4798
male (3716) 3716
cancer (3494) 3494
analysis (3009) 3009
cyclooxygenase-2 (2951) 2951
female (2887) 2887
inflammation (2832) 2832
pharmacology & pharmacy (2539) 2539
cyclooxygenase 2 - metabolism (2529) 2529
mice (2518) 2518
celecoxib (2480) 2480
reports (2178) 2178
expression (2151) 2151
rats (2055) 2055
nonsteroidal antiinflammatory drugs (2034) 2034
care and treatment (2010) 2010
prostaglandins (1912) 1912
oncology (1808) 1808
drugs (1792) 1792
apoptosis (1791) 1791
nitric oxide (1714) 1714
biochemistry & molecular biology (1631) 1631
enzymes (1552) 1552
cyclooxygenase 2 (1543) 1543
universities and colleges (1459) 1459
middle aged (1401) 1401
nonsteroidal anti-inflammatory drugs (1394) 1394
cyclooxygenase inhibitors - pharmacology (1358) 1358
health aspects (1293) 1293
physiological aspects (1230) 1230
cyclooxygenase 2 - genetics (1217) 1217
cyclooxygenase 2 inhibitors - pharmacology (1156) 1156
adult (1153) 1153
aged (1150) 1150
cell biology (1150) 1150
prevention (1150) 1150
chemistry, medicinal (1145) 1145
oncology, experimental (1138) 1138
pharmaceutical industry (1132) 1132
inhibition (1103) 1103
membrane proteins (1074) 1074
cells (1057) 1057
drug therapy (1032) 1032
nf-kappa-b (1011) 1011
dose-response relationship, drug (983) 983
cyclooxygenase (952) 952
sulfonamides - pharmacology (951) 951
mitogens (946) 946
gene expression (939) 939
activation (936) 936
medical research (936) 936
cell line, tumor (928) 928
risk factors (923) 923
prostaglandins e (914) 914
osteoarthritis (903) 903
aspirin (896) 896
immunohistochemistry (890) 890
cyclooxygenase 2 inhibitors (884) 884
proteins (869) 869
oxidative stress (861) 861
neurosciences (855) 855
immunology (811) 811
prostaglandin-endoperoxide synthases - metabolism (811) 811
anti-inflammatory agents, non-steroidal - pharmacology (804) 804
rheumatoid-arthritis (789) 789
rofecoxib (785) 785
in-vitro (778) 778
indomethacin (768) 768
macrophages (767) 767
medicine, experimental (763) 763
anti-inflammatory agents, non-steroidal - adverse effects (739) 739
nitric-oxide synthase (730) 730
anti-inflammatory agents, non-steroidal - therapeutic use (715) 715
rats, sprague-dawley (711) 711
rodents (709) 709
prostaglandin endoperoxide synthase (703) 703
cell line (695) 695
pain (690) 690
gene-expression (687) 687
disease models, animal (684) 684
angiogenesis inhibitors (681) 681
tumors (680) 680
nsaids (678) 678
cyclooxygenase inhibitors - therapeutic use (677) 677
rats, wistar (673) 673
dinoprostone - metabolism (670) 670
development and progression (664) 664
abridged index medicus (658) 658
cells, cultured (657) 657
rna (653) 653
cox-2 inhibitor (646) 646
analgesics (644) 644
cytokines (640) 640
cyclooxygenase 2 inhibitors - therapeutic use (636) 636
pyrazoles - pharmacology (631) 631
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (22971) 22971
German (95) 95
French (42) 42
Spanish (37) 37
Japanese (36) 36
Chinese (26) 26
Korean (24) 24
Polish (13) 13
Russian (12) 12
Portuguese (11) 11
Czech (6) 6
Italian (6) 6
Slovak (4) 4
Romanian (2) 2
Croatian (1) 1
Hungarian (1) 1
Lithuanian (1) 1
Persian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Gastroenterology and Hepatology, ISSN 1542-3565, 2016, Volume 14, Issue 6, pp. 809 - 815.e1
Journal Article
Pharmacoepidemiology and Drug Safety, ISSN 1053-8569, 10/2017, Volume 26, Issue 10, pp. 1141 - 1148
PurposeTo assess the risk of gastrointestinal perforation, ulcers, or bleeding (PUB) associated with the use of conventional nonsteroidal anti-inflammatory... 
proton pump inhibitors | bleeding | gastrointestinal toxicity | perforation | selective COX‐2 inhibitors | ulcers | conventional NSAIDs | selective COX-2 inhibitors | RHEUMATOID-ARTHRITIS | CARDIOVASCULAR EVENTS | NONSELECTIVE NSAIDS | CELECOXIB | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | CONTROLLED TRIALS | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | HIGH-RISK | CYCLOOXYGENASE-2 INHIBITORS | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | OSTEOARTHRITIS | Age Factors | Humans | Middle Aged | Peptic Ulcer - prevention & control | Male | Peptic Ulcer - epidemiology | Gastrointestinal Hemorrhage - epidemiology | Case-Control Studies | Cyclooxygenase 2 Inhibitors - adverse effects | Peptic Ulcer Perforation - epidemiology | Pain - drug therapy | Pain Management - adverse effects | Aged, 80 and over | Female | Odds Ratio | Peptic Ulcer - complications | Risk Factors | Pain Management - methods | Proton Pump Inhibitors - therapeutic use | Gastrointestinal Hemorrhage - chemically induced | Gastrointestinal Hemorrhage - prevention & control | Peptic Ulcer Perforation - prevention & control | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Aged | Peptic Ulcer - chemically induced | Peptic Ulcer Perforation - etiology | COX-2 inhibitors | Proton pump inhibitors | Nonsteroidal anti-inflammatory drugs | Drugs | Antiinflammatory agents | Control methods | Adjustment | Toxicity | Perforation | Pharmacology | Inflammation | Regression analysis | Patients | Risk factors | Bleeding | Nonsteroidal antiinflammatory drugs | Confidence intervals | Inhibitors | Ulcers | Cyclooxygenase-2 | Health risk assessment | Index Medicus | Original Report | Original Reports
Journal Article
European Journal of Medicinal Chemistry, ISSN 0223-5234, 08/2016, Volume 118, pp. 250 - 258
Two new series of 1,5-diaryl pyrazoles ( , , , and ) and 1,5-diaryl pyrazoline ( and were prepared as both Cyclooxygenase-2 and 15-lipoxygenase inhibitors.... 
15-Lipoxygenase inhibitors | Ethyl trifloroacetate | SO2NH2 pharmacophores | Cyclooxygenase inhibitors | Celecoxib analogues | DMFDMA | Anti-inflammatory | pharmacophores | CHEMISTRY, MEDICINAL | COX-2 | LEUKOTRIENES | CYCLOOXYGENASE | PROSTAGLANDINS | INFLAMMATION | BIOLOGICAL EVALUATION | AGENTS | 5-LIPOXYGENASE | MEDIATORS | DERIVATIVES | Stereoisomerism | Anti-Inflammatory Agents, Non-Steroidal - chemistry | Male | Cyclooxygenase 2 Inhibitors - chemistry | Celecoxib - chemistry | Anti-Inflammatory Agents, Non-Steroidal - pharmacology | Cyclooxygenase 2 Inhibitors - adverse effects | Lipoxygenase Inhibitors - chemical synthesis | Pyrazoles - chemistry | Lipoxygenase Inhibitors - chemistry | Cattle | Celecoxib - chemical synthesis | Anti-Inflammatory Agents, Non-Steroidal - chemical synthesis | Celecoxib - adverse effects | Cyclooxygenase 2 Inhibitors - chemical synthesis | Chemistry Techniques, Synthetic | Cyclooxygenase 2 Inhibitors - pharmacology | Magnetic Resonance Spectroscopy | Rats | Celecoxib - pharmacology | Arachidonate 15-Lipoxygenase - metabolism | Lipoxygenase Inhibitors - adverse effects | Ulcer - chemically induced | Animals | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Cyclization | Cyclooxygenase 2 - metabolism | Thiazoles - chemistry | Lipoxygenase Inhibitors - pharmacology | COX-2 inhibitors | Carrageenin | Nuclear magnetic resonance | Celecoxib | Angiogenesis inhibitors | Liability (Law) | Index Medicus
Journal Article
European Journal of Medicinal Chemistry, ISSN 0223-5234, 2012, Volume 47, Issue 1, pp. 111 - 124
Balanced modulation of several targets is one of the current strategies for the treatment of multi-factorial diseases. Based on the knowledge of inflammation... 
Multi-target drugs | Benzo/benzisothiazolidinones | Inflammation | Lipoxygenase inhibitors | COX-1/2 inhibitors | Fragment-based drug design | CHEMISTRY, MEDICINAL | CYCLOOXYGENASE-2 | MECHANISM | CRYSTAL-STRUCTURE | LIPOXYGENASES | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | COX-2 INHIBITORS | DUAL INHIBITORS | DERIVATIVES | ANTIMICROBIAL ACTIVITY | LIGAND DESIGN | Thiazolidines - chemical synthesis | Thiazolidines - metabolism | Male | Structure-Activity Relationship | Anti-Inflammatory Agents - metabolism | Lipoxygenase - metabolism | Lipoxygenase Inhibitors - chemical synthesis | Lipoxygenase Inhibitors - chemistry | Drug Design | Cyclooxygenase 1 - chemistry | Female | Thiazolidines - pharmacology | Thiazolidines - chemistry | Catalytic Domain | Cyclooxygenase Inhibitors - metabolism | Anti-Inflammatory Agents - pharmacology | Cyclooxygenase 2 - chemistry | Models, Molecular | Cyclooxygenase Inhibitors - chemistry | Edema - drug therapy | Lipoxygenase - chemistry | Cyclooxygenase Inhibitors - pharmacology | Animals | Anti-Inflammatory Agents - chemistry | Cyclooxygenase 2 - metabolism | Cyclooxygenase Inhibitors - chemical synthesis | Anti-Inflammatory Agents - chemical synthesis | Lipoxygenase Inhibitors - metabolism | Mice | Cyclooxygenase 1 - metabolism | Edema - chemically induced | Lipoxygenase Inhibitors - pharmacology | COX-2 inhibitors | Enzymes | Index Medicus
Journal Article
European Journal of Medicinal Chemistry, ISSN 0223-5234, 06/2014, Volume 80, pp. 167 - 174
A novel series of 2-phenyl-5-(1,3-diphenyl-1 -pyrazol-4-yl)-1,3,4-oxadiazoles were designed and synthesized for selective COX-2 inhibition with potent... 
Analgesic | 1,3,4-Oxadiazole | COX-2 | Anti-inflammatory | Pyrazole | Molecular docking analysis | 1 3 4-Oxadiazole | CHEMISTRY, MEDICINAL | CYCLOOXYGENASE-2 | PYRAZOLE DERIVATIVES | ANTICANCER AGENTS DESIGN | ANALGESIC AGENTS | DRUGS | BIOLOGICAL EVALUATION | SUBSTITUTED THIAZOLIDIN-4-ONES | DUAL INHIBITORS | 1,3,4-OXADIAZOLES | PHARMACOLOGICAL EVALUATION | Analgesics - pharmacology | Humans | Analgesics - metabolism | Substrate Specificity | Male | Structure-Activity Relationship | Anti-Inflammatory Agents, Non-Steroidal - pharmacology | Cyclooxygenase 2 Inhibitors - adverse effects | Analgesics - chemical synthesis | Oxadiazoles - pharmacology | Cyclooxygenase 2 Inhibitors - metabolism | Anti-Inflammatory Agents, Non-Steroidal - metabolism | Anti-Inflammatory Agents, Non-Steroidal - chemical synthesis | Analgesics - adverse effects | Cyclooxygenase 2 Inhibitors - chemical synthesis | Stomach Ulcer - chemically induced | Chemistry Techniques, Synthetic | Oxadiazoles - chemical synthesis | Cyclooxygenase 2 Inhibitors - pharmacology | Cyclooxygenase 2 - chemistry | Rats | Oxadiazoles - adverse effects | Animals | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Cyclooxygenase 2 - metabolism | Protein Conformation | Mice | Molecular Docking Simulation | Cyclooxygenase 1 - metabolism | Oxadiazoles - metabolism | COX-2 inhibitors | Aspirin | Carrageenin | Analysis | Drugstores | Acetic acid | Organic acids | Index Medicus
Journal Article
Science, ISSN 0036-8075, 6/2012, Volume 336, Issue 6087, pp. 1386 - 1387
Journal Article
Fundamental & Clinical Pharmacology, ISSN 0767-3981, 10/2019, Volume 33, Issue 5, pp. 535 - 543
This study was designed to observe the compensation between cyclooxygenase‐2 pathway and 5‐lipoxygenase pathway in chronic aluminum overload‐induced liver... 
liver injury | compensation | aluminum | cyclooxygenase‐2 | 5‐lipoxygenase | Meloxicam | Immunohistochemistry | COX-2 inhibitors | Liver diseases | Liver | Oxidative stress | Aluminum | Caffeic acid | Prostaglandin endoperoxide synthase | Histopathology | Inhibitors | Acids | Tumor necrosis factor | Liquid oxygen | Compensation | Lipoxygenase | Injuries | Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2007, Volume 369, Issue 9573, pp. 1621 - 1626
Summary Background Guidelines on pain management recommend that patients at risk of ulcers receive either a cyclo-oxygenase (COX 2) inhibitor or a... 
Internal Medicine | ESOMEPRAZOLE | MEDICINE, GENERAL & INTERNAL | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | NSAID | CYCLOOXYGENASE-2 INHIBITORS | ARTHRITIS PATIENTS | NAPROXEN | COMPLICATIONS | HELICOBACTER-PYLORI | PEPTIC-ULCER | CELECOXIB | Pyrazoles - therapeutic use | Humans | Esomeprazole - adverse effects | Male | Secondary Prevention | Osteoarthritis - drug therapy | Esomeprazole - therapeutic use | Peptic Ulcer Hemorrhage - prevention & control | Female | Drug Therapy, Combination | Pyrazoles - adverse effects | Anti-Ulcer Agents - therapeutic use | Double-Blind Method | Proton Pump Inhibitors | Risk Factors | Anti-Ulcer Agents - adverse effects | Peptic Ulcer Hemorrhage - chemically induced | Treatment Outcome | Celecoxib | Peptic Ulcer Hemorrhage - therapy | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Sulfonamides - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Sulfonamides - adverse effects | Aged | Cyclooxygenase Inhibitors - adverse effects | Cyclooxygenase Inhibitors - therapeutic use | Prevention | Complications and side effects | COX-2 inhibitors | Relapse | Gastrointestinal bleeding | Peptic ulcer | Proton pump inhibitors | Dosage and administration | Drug therapy | Diseases | Drugs | Medical research | Physical examinations | Hospitals | Analgesics | Ulcers | Terminal illnesses | Clinical trials | Pharmaceuticals | Index Medicus | Abridged Index Medicus
Journal Article
European Journal of Medicinal Chemistry, ISSN 0223-5234, 11/2016, Volume 123, pp. 803 - 813
Two new series of -substituted indole derivatives and were synthesized. Their chemical structures were confirmed using spectroscopic tools including IR, H NMR,... 
Molecular docking study | Anti-inflammatory activity | Antiproliferative activity | Indole derivatives | Cyclooxygenase enzymes | DESIGN | CHEMISTRY, MEDICINAL | INDOMETHACIN | CELECOXIB | SELECTIVE COX-2 INHIBITORS | LIPOXYGENASES | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | INFLAMMATION | ESTERS | AGENTS | DERIVATIVES | Antineoplastic Agents - chemical synthesis | Humans | Indoles - chemical synthesis | Cyclooxygenase 2 Inhibitors - chemistry | Anti-Inflammatory Agents - metabolism | Antineoplastic Agents - metabolism | Indoles - metabolism | Lipoxygenase Inhibitors - chemical synthesis | Lipoxygenase Inhibitors - chemistry | Arachidonate 5-Lipoxygenase - chemistry | Drug Design | Indoles - pharmacology | Antineoplastic Agents - pharmacology | Cyclooxygenase 2 Inhibitors - metabolism | Cyclooxygenase 2 Inhibitors - chemical synthesis | Catalytic Domain | Chemistry Techniques, Synthetic | Arachidonate 5-Lipoxygenase - metabolism | Cyclooxygenase 2 Inhibitors - pharmacology | Anti-Inflammatory Agents - pharmacology | Antineoplastic Agents - chemistry | Anti-Inflammatory Agents - chemistry | Schiff Bases - chemistry | Cyclooxygenase 2 - metabolism | Cell Line, Tumor | Anti-Inflammatory Agents - chemical synthesis | Lipoxygenase Inhibitors - metabolism | Molecular Docking Simulation | Cyclooxygenase 1 - metabolism | Indoles - chemistry | Lipoxygenase Inhibitors - pharmacology | Schiff bases | COX-2 inhibitors | Analysis | Phytochemistry | Pharmacy | Drugstores | Nuclear magnetic resonance spectroscopy | Mass spectrometry | Cells | Index Medicus
Journal Article